linjc16/ctgov huggingface dataset:
Transcranial Direct Current Stimulation of the Primary Motor Cortex to Treat Levodopa-induced Dyskinesias

Study Overview
=================
Brief Summary
-----------------
The main objective of the study is to evaluate the efficacy of 10 sessions of transcranial direct current stimulation of the primary motor cortex to reduce levodopa-induced dyskinesia

Official Title
-----------------
Transcranial Direct Current Stimulation of the Primary Motor Cortex to Treat Levodopa-induced Dyskinesias in Patients With Parkinson's Disease.

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Device: Transcranial direct current stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with diagnosis of idiopathic Parkinson's disease according to Movement Disorder Society (MDS) criteria and levodopa-induced dyskinesia; age between 30 and 80 years; ongoing therapy with levodopa; fulfillment of requirements for the application of transcranial magnetic stimulation (TMS), assessed by completion of the TMS screening questionnaire. Exclusion Criteria: patients unable to give informed consent; cognitive impairment (MMSE ≤ 24); history of epilepsy; pregnant women.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active stimulation<br>Ten sessions of cathodic transcranial direct current stimulation over primary motor cortex | Device: Transcranial direct current stimulation<br>* Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia<br>|
| Sham Comparator: Sham stimulation<br>Ten sessions of sham stimulation over primary motor cortex | Device: Transcranial direct current stimulation<br>* Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of dyskinesia | Change in the total score of part III of the Unified Dyskinesia Rating Scale (range 0-112, 112 is the worse outcome) in on motor state at the assessment made three days after the end of treatment compared with the assessment made at baseline in the groups of patients treated with tDCS and sham-stimulation, respectively | 15 days |
PRO Survivorship Concerns ITA

Study Overview
=================
Brief Summary
-----------------
Breast cancer survivors typically experience fatigue, pain, insomnia, depression, anxiety, difficulty in concentrating, memory impairment, body image problems, vaginal dryness, interest in sex decreasing, hot flashes, gain weight, and infertility. All of these problems affect quality of life (QoL) mainly during the early survival and they become even more important to understand and address if long-term effects could be prevented. The use of PROs in care settings has demonstrated improvement in provider/patient communication, recognition of previously unrecognized issues, as well as patient satisfaction with care. In order to allow to patients the use of the PRO survivorship concerns in their mother tongue, it is imprtant to have validated translations with transcultural adaptation. The main goals of this multicentric study are the translation, adaptability and transcultural validation of the PRO questionnaire survivorship concerns to put in evidence rehabilitation needs in breast cancer patients in early stage.

Official Title
-----------------
Rehabilitation Needs in Patients With Early Breast Cancer: Validation of a Questionnaire Patient Reported Outcome

Conditions
-----------------
Breast Neoplasm Female, Quality of Life, Psychological Distress

Intervention / Treatment
-----------------
* Behavioral: Patient Reported Outcome (PRO)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: During transcultural adaptability 80 representative patients will be recruited . During the validation phase previus patients will be included and more other patients will be included (at least 280) Exclusion Criteria: Patients with cognitive or memory impairment wil be excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Patient Reported Outcome (PRO)|Quality of Life evaluation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Translation and validation of questionnaire PRO | The main goals of this multicentric study are the translation, adaptability and transcultural validation of the PRO questionnaire survivorship concerns to put in evidence rehabilitation needs in breast cancer patients in early stage. the PRO questionnaire survivorship concerns is made up of 17 items which evaluate the problems of survival, the level of concern about problems related to the care of patients, screening, symptom management, family and genetic problems and the fear of disease recurrence, on a scale of 0 to 3.It will be administered twice 15 days apart and in order to identify the levels of agreement between the two assessments, the Interclass Correlation Coefficient (ICC) model 3.1 will be applied and calculated for each item. | 6 months |
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.

Official Title
-----------------
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML) Using Remote Symptom Monitoring

Conditions
-----------------
Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia

Intervention / Treatment
-----------------
* Other: Web based survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All participants must be 18 years of age or older. Subjects may be any stage and anywhere in the treatment continuum. Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma. Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer. All participants must be able to understand English. Exclusion Criteria: Any patient who cannot understand written or spoken English. Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer. Any patient on a treatment clinical trial. Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Web based survey|online weekly survey|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Create Data Set | The goal of this registry is to create a data set from real world clinical and patient reported data collected using an electronic care planning system (CPS) that is used in routine care for cancer patients on active treatment | 1 year |
Establishment and Validation of a Clinical Predictive Model for Gastrointestinal Cancer Screening Based on Patient-related Risk Factors

Study Overview
=================
Brief Summary
-----------------
Gastrointestinal tumors (esophageal cancer, gastric cancer, colorectal cancer) seriously threaten human health, with a high incidence rate and cancer related hope mortality. Digestive endoscopy is the main method for screening gastrointestinal tumors. Early screening of gastrointestinal tumors can improve the detection of early cancer and improve prognosis. The five-year survival rate of early stage tumors after comprehensive treatment can reach 90%, while the five-year survival rate of late stage tumors is less than 30%. Therefore, the screening of gastrointestinal tumors is very important. Studies have shown that there are similarities in risk factors for gastrointestinal tumors, such as age, gender, family history, smoking, alcohol consumption, etc. Currently, established digestive malignancies are targeted at a single malignant tumor. At present, there is a lack of understanding of the overall risk factors associated with gastrointestinal tumors and the establishment of relevant risk prediction models. Therefore, we conducted a prospective, multicenter cross-sectional study to explore the independent risk factors of combined gastrointestinal tumors and establish a risk prediction model for combined screening of gastrointestinal tumors.

Official Title
-----------------
Establishment and Validation of a Clinical Predictive Model for Gastrointestinal Cancer Screening Based on Patient-related Risk Factors: a Prospective, Multicenter Cross-sectional Study

Conditions
-----------------
Malignant Tumor of Digestive Tract, Risk Factors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals aged 18-80 who undergo both gastroscopy and colonoscopy simultaneously Exclusion Criteria: （1）Previously diagnosed with esophageal, gastric, or colorectal cancer; (2) Suspected presence of gastrointestinal obstruction or perforation; (3) Previous history of esophageal, gastric, or colorectal surgery; (4) Those who are not suitable for endoscopic examination due to serious diseases or unstable hemodynamics; (5) Individuals who are unable to obtain relevant information due to communication barriers such as mental or neurological disorders; (6) Pregnancy or lactation period; (7) Not willing or unable to sign the informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall detection rate of gastrointestinal cancer | The proportion of at least one type of gastrointestinal malignant tumor detected | 2 years |
Prediction Of Serious Adverse Event in Emergency Department With dysKAlemia, Retrospective Study

Study Overview
=================
Brief Summary
-----------------
Dyskalemia, hypo- and hyperkalemia are common in the emergency department and are associated with increased morbidity and mortality. The potential seriousness of dyskalemia results from the potential alteration of intracardiac conduction and the increase in cardiac rhythm disorders, all associated with a lethal risk. Given the aspecific symptoms of dyskalemia and the complex causal links to be acquired, it is difficult to judge the severity of the disorders in front of an initial clinical presentation of a patient in the emergency room, as the patient may present a serious condition during his stay in the emergency room, related to the dyskalemia and not prejudged at first. The ECG is recommended to judge the severity of the disorder, in association with the level of kalemia, but the electrical changes of its pattern in the context of dyskalemia are sometimes so fine that even the eye of the practitioner is not able to detect them. To date and to our knowledge, there is no tool for predicting the risk of RTA or death in dyskalemia. The existing studies on the subject, including ECGs, seek to detect dyskalemia and not its complications, and the proposed tools only take into account the ECG and not the clinical context of the patient.

Official Title
-----------------
Prediction Of Serious Adverse Event in Emergency Department With dysKAlemia, Retrospective Study

Conditions
-----------------
Emergencies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major patient consulting in an emergency department participating in the study who received at least a digital ECG AND an ionogram in the emergency department during the study period Exclusion Criteria: Patient who has expressed opposition to the reuse of their data for the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with Cardiac arrest and/or rhythm disorder | Number of patients with Cardiac arrest and/or rhythm disorder within 48 hours of the ED visit | within 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Mortality | Rate of Mortality : all causes combined (SAU, hospitalization, SMUR, home) | within 48 hours | 
| The type of received treatment for dyskalemia | The type of treatment received for dyskalemia (IV and what type, orally and what type) | within 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
artificial intelligence, kalemia, dyskalemia
Alleged Drug Allergies in Military General Medicine: Patients' Experiences and Beliefs

Study Overview
=================
Brief Summary
-----------------
This study focuses on the experience of the military patient reporting a suspected drug allergy, with its own specificities. Suspicions of drug allergies during a mission expose the doctor to difficulties. This study will improve understanding of the allergy patient's point of view. The end result could be a set of ideas for measures to raise awareness among these patients, and motivate them to undergo an allergological assessment.

Official Title
-----------------
Alleged Drug Allergies in Military General Medicine: Patients' Experiences and Beliefs (ALLMED)

Conditions
-----------------
Allergy Penicillin

Intervention / Treatment
-----------------
* Other: Interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Military personnel (active or reservist) Reporting a drug allergy during a periodic medical check-up or during a consultation in a medical unit Not opposed to participating in the study. Exclusion Criteria: Candidate on admission visit Opposition to study Minor (under 18 years of age) Pregnant, parturient or breast-feeding woman Person deprived of liberty by a judicial or administrative decision, person under psychiatric care Non-French nationals Person of full age subject to a legal protection measure Person unable to express non-opposition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Interview<br>Monocentric qualitative study with a descriptive socio-demographic section, a descriptive qualitative section on the experience and perception of allergy, then on the obstacles to allergological assessment, and finally a descriptive quantitative section to evaluate knowledge of antibiotic therapy. | Other: Interview<br>* Semi-structured interview on experiences, perceptions, beliefs and knowledge of drug allergy and barriers to allergological testing, with a view to content analysis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' experiences of drug allergies | describe patients' experiences, perceptions, beliefs and knowledge of drug allergies in general practice in the army | Through study completion (12 months) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' obstacles | describe the obstacles to allergological assessment | Through study completion (12 months) |
QDOT Based PVI for Atrial Fibrillation Treatment - The peQasus Study

Study Overview
=================
Brief Summary
-----------------
PeQasus is a worldwide, retrospective, multicenter analysis focusing on QDOT based PVI. Data of at least 300 patients with QDOT based PVI will be collected. All data will be evaluated after anonymization. Primary endoints are efficacy and safety.

Official Title
-----------------
Very High-Power Short-duration Ablation Utilizing the QDOT Micro Ablation Catheter for Pulmonary Vein Isolation - A Multicenter Study.

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: pulmonary vein isolation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suitable for PVI Exclusion Criteria: Non suitable for PVI
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: pulmonary vein isolation|pulmonary vein isolation utilizing the QDOT Micro ablation catheter|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of the procedure | Acute PVI | Periprocedural | 
| Saftey (Cardiac tamponade) | Periprocedural complications (occurence of cardiac tamponade) | Periprocedural | 
| Safety (Stroke) | Periprocedural complications (occurence of stroke) | Periprocedural | 
| Safety (Bleeding) | Periprocedural complications (occurence of puncture site bleeding) | Periprocedural | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Procedure time |  | Periprocedural | 
| LA dwelling time |  | Periprocedural | 
| First pass isolation |  | Periprocedural | 
| 12 months follow-up | Occurence of aftrial fibrillation or atrial tachycardia >30 Seconds between 91 days and 12 months of follow-up | 91 days - 12 months after the procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Catheter abaltion, very high-power short-duration, QDOT
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA

Study Overview
=================
Brief Summary
-----------------
The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for SIR-Spheres treatment for hepatocellular carcinoma.

Detailed Description
-----------------
The investigation is a prospective, single center, open label, single-arm study. Patients enrolled in the study will have 3 imaging scans taken after 99mTc-MAA injection, the final of which will occur between 18 and 24 hours post-injection.

Official Title
-----------------
Study to Calculate the Radiation-Absorbed Dose of Technetium-99m Macroaggregated Albumin (99mTc-MAA) to the Whole Body and Non-Liver Critical Organs

Conditions
-----------------
Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm

Intervention / Treatment
-----------------
* Drug: 99mTc-Macro Albumin Aggregate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing, able, and mentally competent to provide written informed consent Age 18 or older at the time of consent Patients who are being evaluated for SIR-Spheres treatment eligibility Exclusion Criteria: Patients who are contraindicated for SIR-Spheres treatment Patients who are contraindicated for 99mTc-MAA per the manufacturer's package insert

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 99mTc-MAA Injection<br>Patients enrolled in the study will have 3 imaging scans taken after 99mTc-MAA Injection with the final scan occurring 18-24 hours after injection. | Drug: 99mTc-Macro Albumin Aggregate<br>* Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean absorbed dose (Gy) for the whole body |  | 18-24 hours | 
| Mean absorbed dose (Gy) for critical non-liver organs |  | 18-24 hours | 
| Mean activity (Bq) for the whole body |  | 18-24 hours | 
| Mean activity (Bq) for critical non-liver organs |  | 18-24 hours | 
| Effective dose (Gy) for the whole body |  | 18-24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Technetium-99m macroaggregated-albumin (99mTc-MAA), SIR-Spheres Y90 resin microspheres treatment